Such dietary choices are part of a more complex set of necessary sociopolitical, economic and technological correctives identified by Michael Grunwald in his 2025 book, "We Are Eating the Earth: The ...
Developed by Ascentage Pharma, lisaftoclax is an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors. Lisaftoclax is ...
Developed by Ascentage Pharma, olverembatinib is the first China-approved third-generation BCR-ABL inhibitor, currently being jointly commercialized in China by Ascentage Pharma and Innovent Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback